Latest Strategic Collaborations News

Scout Security reported a significant 62% reduction in operating cash outflows for Q3 FY2025, while advancing a potential acquisition and partnership opportunities following CES. The company’s cash position remains tight, prompting ongoing capital raising efforts.

Everest Metals has initiated a 2,500m drilling campaign at its Mt Edon project in Western Australia, aiming to upgrade and expand its significant rubidium resource amid rising global demand for this critical mineral.

Nova Minerals has made a strategic A$1 million investment in Adelong Gold, securing a 9.4% stake and board representation, while maintaining focus on its flagship Estelle Project in Alaska.

Adelong Gold has locked in a $1.25 million strategic investment from Nova Minerals and Barclay Wells clients, enabling accelerated exploration at its NSW and Victorian gold-antimony projects.

Hazer Group and First Graphene have signed a non-binding MOU to explore innovative applications for Hazer’s proprietary graphite, aiming to capitalize on rising global demand amid supply constraints.

4DS Memory Limited has had its trading suspension lifted following an important announcement about its collaboration with development partners to chart the future of its technology beyond 2025.

Metallium Ltd has appointed former U.S. Deputy Assistant Secretary of Defense Travis Langster to its U.S. advisory board, aiming to strengthen ties with government and industry for critical metals supply chain resilience.

Provaris Energy has formalized a strategic collaboration with Baker Hughes to advance compressed hydrogen solutions for marine transport and storage across Europe, marking a key milestone in scaling regional hydrogen supply chains.

Iron Road Ltd has agreed revised terms with Revera Energy to extend and adjust land purchase options critical to the Cape Hardy green hydrogen project in South Australia.

Scalare Partners Holdings Limited reported a 26% increase in total revenues to $3.54 million for FY25, driven by strong growth in founder support services and strategic acquisitions. However, the Group recorded a statutory loss of $2.65 million amid increased structural and compliance costs following its ASX listing and expansion.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.